Alexander's
ALX | NYSE
$241.76
-$3.75 (-1.53%)
At close: Nov 16, 2026, 4:00 PM ET
$241.76
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:00 PM ET
Alexander's Company Profile
Company profile explainedCompany Profile
Alexander’s, Inc. is a real estate investment trust (REIT) engaged in leasing, managing, developing and redeveloping properties. Alexander’s activities are conducted through its manager, Vornado Realty Trust. Alexander’s has five properties in the greater New York City metropolitan area consisting of: 731 Lexington Avenue office and retail (including Bloomberg, L.P.'s world headquarters), the Rego Center complex in Rego Park, Queens, including the Rego Park I & II retail properties and The Alexander apartment tower, and a retail property located in Flushing, NY. Alexander's, Inc. was incorporated in 1928 and is based in Paramus, United States.
Key Executives
| Name | Position |
|---|---|
| Steven Roth | Chairman of the Board & Chief Executive Officer |
| Gary W. Hansen | Chief Financial Officer |
| Steven J. Borenstein | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 03, 2026 | 10-Q | Quarterly Report |
| Jun 10, 2026 | 4 | Filing |
| May 28, 2026 | 8-K | Current Report |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
Alexander's
| Country | United States |
| IPO Date | Feb 21, 1973 |
| Industry | REIT - Retail |
| Sector | Real Estate |
| Employees | 103 |
| CEO | Steven Roth |
Contact Details
210 Route 4 East Paramus,
New Jersey 07652-5108 United States
Stock Details
| Ticker Symbol | ALX |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000003499 |
| CUSIP Number | 014752109 |
| ISIN Number | US0147521092 |
| SIC Code | 6798 |
Recent News
- 19 hours ago / globenewswire.comALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 6 days ago / globenewswire.comALX Oncology to Present at Upcoming Investor Conferences
- 14 days ago / seekingalpha.comAlexander's, Inc. (ALX) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comAlexander's Q3 Earnings Call Highlights
- 15 days ago / zacks.comAlexander's (ALX) Lags Q3 FFO and Revenue Estimates
- 15 days ago / globenewswire.comAlexander's Announces Third Quarter Financial Results
- 20 days ago / globenewswire.comAlexander's Declares Quarterly $4.50 Dividend on Common Shares
- 29 days ago / globenewswire.comAlexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
- 1 month ago / seekingalpha.comMousetraps: 7 High-Yield REITs Risking Dividend Cuts
- 2 months ago / globenewswire.comALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Add to Watchlist
Select watchlists to add or remove ALX